In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopharma Sizes Up The Affordable Care Act: Buyer’s Remorse Or Winner’s Curse?

Executive Summary

Three years into the ACA, the biopharma industry takes stock of its near-term wins and losses as the law’s critical expanded insurance coverage takes effect beginning in 2014. Pharma still isn’t sure whether the increase in covered lives from the exchanges will boost prescription sales enough to offset the rebates, taxes, and fees it agreed to pay out, or what kind of patients constitute this new market.

You may also be interested in...



Amgen Makes The Case For Growth, Dispenses With Share Buybacks

The promise of late-stage candidates and emerging markets, where it also disclosed a new deal, was the focus for management on its third quarter earnings call. Underscoring its repositioning as an innovative growth company, Amgen said it will not do further share repurchases in the next few years.

START-UP’s 2013 Life Science Venture Capital Survey: Lights, Even Exits, At The End Of A Dark Tunnel

Our third annual survey of institutional and corporate VCs arrives as life science investing reaches a crossroads. Public markets are gung ho for new biotech companies, lifting the spirits of a subset of our respondents, but VCs still face big hurdles to raise new funds.

ACA Countdown: Details Emerging On Exchanges, Medicaid Expansion

Open enrollment in state exchange plans kicks off Oct. 1 and expanded Medicaid eligibility Jan. 1, and many states offer a preliminary view of how coverage will play out under the Affordable Care Act in 2014.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV004067

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel